Oklo shares were last seen trading near $44, after a steep retreat from their 52-week high of $193.84. The stock’s collapse has persisted despite operational progress, including the company reporting its first-ever quarterly revenue and its Groves Isotope Test Reactor in Texas reaching first criticality less than a year after groundbreaking.
Investors appear to have been reassessing Oklo’s long-dated path to commercial power, while the new milestones address near-term skepticism about whether the company could build and operate a nuclear facility on a fast timeline.
Key takeaways
- Price move: Oklo shares are down sharply from the 52-week high near $193.84 and are trading around $44.
- Catalyst: Oklo reported first-quarter historical revenue of about $1.2 million and said its Groves reactor reached first criticality in Lockhart, Texas, in early August.
- Operational implication: A reactor milestone signals execution on infrastructure and testing, not just development claims.
- Investor implication: The stock’s drawdown suggests the market previously priced in far more optimistic timing and scaling toward commercial power.
- Ongoing risk: Losses remain substantial as the company continues spending to de-risk early projects.
What drove the company’s milestones
Oklo reported its first-ever quarterly revenue in the second quarter, totaling about $1.2 million. According to the company, most of this revenue came from engineering and consulting services. Data indicates a meaningful portion of that revenue was tied to businesses Oklo acquired in June, making the result more “purchased start” than purely organic traction.
Beyond early revenue, Oklo’s broader proving point centered on its Texas facility. In early August, the company said its Groves Isotope Test Reactor reached first criticality—defined as a controlled, self-sustaining nuclear reaction—less than a year after groundbreaking. Oklo said Groves is the first reactor in the U.S. Department of Energy’s Reactor Pilot Program to reach first criticality on private land, built from scratch.
The reactor is designed to produce isotopes intended for healthcare, industrial, and national security applications. While the milestone does not by itself validate long-term commercial profitability, it directly addresses whether Oklo can bring an operating nuclear system online on its planned schedule.
The market drawdown reflects expectations, not execution
Oklo’s stock performance underscores a central disconnect: business progress improved while the share price fell. At the 52-week high of $193.84, investors were effectively paying for a forward-looking scenario that included profitable plants and data-center power arrangements appearing earlier and scaling more smoothly than what the company had yet demonstrated.
The drawdown suggests that, at the peak, the market price incorporated years of execution and financial outcomes that were not yet supported by operating revenue or commercial plant performance. Oklo remains in the investment phase, with its first commercial power plant still under construction, while it continues to incur large losses.
Even after the stock moved down to roughly $44, the valuation implied by the remaining market capitalization remains elevated relative to current revenue, according to figures described in the report. The implication is that investors are still underwriting a future expansion in revenue and operational output, but with less confidence in timing and risk management than they had at the earlier peak.
Where the numbers still weigh on the stock
Despite the two milestones—first-ever quarterly revenue and first criticality—Oklo’s financial profile remains heavily loss-making. The report said the company has lost about $153 million over the past 12 months, and that management is spending faster to reduce risks around its first projects rather than slowing down.
For investors, that dynamic matters because nuclear development timelines and regulatory and construction risks can be difficult to compress. In that context, the stock’s valuation will likely continue to hinge on the company’s ability to translate engineering milestones into repeatable commercial progress—such as sustained operations, customer contracting, and incremental revenue beyond services.
What to watch next
Next, investors are likely to focus on whether Oklo can build on the reactor milestone with measurable progress toward commercial deployment, additional revenue visibility beyond engineering and consulting, and clearer timelines for scaling. The company’s upcoming updates—particularly around project execution, financing, and any near-term revenue contribution from Groves and related efforts—will be key to determining whether the market’s reduced expectations continue to stabilize the stock or if further repricing is likely.
